and the study was conducted in accordance with the principles of laboratory animal care.
INTRODUCTION
Colorectal cancer is one of the most universally diag nosed gastrointestinal cancers and among the main causes of cancerrelated death in western developed countries [1, 2] . Despite advanced chemotherapeutic treatments, more than 130000 new cases of colon cancer are diagnosed each year [3] , causing more than 56000 deaths/year in America [4] . Thymoquinone (TQ) is a phytochemical compound isolated from Nigella sativa that possesses anticarcinogenic activity and induces apoptosis in tumor cells, and it can interfere with cancer cell survival through different mechanisms [5, 6] . Available treatments for cancer include surgical removal, chemotherapy and adjuvant chemotherapy for patients who are strong enough to undergo it. To date, the surgical removal of cancer tissue is considered the most appropriate way to address colon cancer. Our present study investigated the use of phytochemical drugs as a supplementary chemotherapy approach. Laboratory studies have shown that TQ significantly inhibits oral cancer through the p38β MAPK family [7] . Among the hereditary colon cancers, hereditary nonpolyposis colon cancer (HNPCC) patients present a particularly high risk for synchronous metastasis via the lymphatic system [8, 9] . In this study, we used the colorectal cancer cell line LoVo, which was developed from a 56year old colon cancer patient. Many previous studies have verified that prostaglandin E2 (PGE2) promotes cancer development and have considered it a cancer marker; therefore, we used PGE2 as a control [1012] . PGE2
seems to assist cell survival in colorectal cancer cells by augmenting RasMAPK signaling [13] . Compared to normal intestinal tissues, COX2 expression is 80%90% higher in colorectal cancers. Cancers of the head, breast, cervix, bladder and gastrointestinal system have also shown high levels of COX2 expression [1416] . COX-2/PGE2 signaling affects cell physiology in multiple tumor types and maintains colorectal tumorigenesis [12, 17] . PGE2 as a proangiogenic factor is associated with transformed vascular permeability and angiogenesis [18] . COX2
expression is thought to contribute to the principal PGE2 metabolic product [19, 20] . Some nonsteroidal anti inflammatory drugs (NSAIDs) and vegetables produce anti-tumor effects that reduce PGE2 synthesis or inhibit COX2 [2124] . In our experiments, we sought to identify compounds similar to NSAIDs or adjunct drugs to increase the effectiveness of cancer chemotherapy. Our experimental drug, TQ, has promising antitumor effects, and it inhibited the incidence of forestomach tumors and fibrosarcoma tumors and increased cellular longevity [25, 26] . We previously evaluated PGE2-induced migration in human LoVo cancer cells, and the major mechanism involves the activation of the pAkt/ p-PI3K/p-GSK3β/βcatenin pathway that ultimately up regulates COX2 expression (unpublished data). After the addition of TQ, the exact anticancer mechanism produced by PGE2 was determined. Previous studies have demonstrated that βcatenin translocation, which includes cointeraction with and activation of the promoters LEF-1 and TCF-4, subsequently modulates downstream gene expression [27] . The nuclear cofactors LEF and TCF were triggered to initiate the transcription and translation of COX2 [28] . Cell metastasis efficiency is a focus of our work because it correlates with COX2 activity [29, 30] . Moreover, cell migration is promoted due to COX2 expression [31] . Numerous studies of animals treated with TQ have demonstrated that TQ is not toxic [3234] . Our study used immunoblotting assays, immuno fluorescence assays, nuclear extraction and in vivo experiments to examine the COX2 protein, which affects the metastasis of highly metastatic LoVo cancer cells treated with TQ.
MATERIALS AND METHODS

Cells, antibodies, reagents, and enzymes
The human colon cancer cell line LoVo was obtained from the American Tissue Culture Collection (ATCC) (Rockville, MD, United States). LoVo cells were established from metastatic nodules that were resected from a 56yearold colon adenocarcinoma patient.
We utilized antibodies against the following proteins: phosphoPI3K, phosphoAkt, COX2, phospho-GSK3β, β-catenin, LEF-1, HADAC-1 (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, United States), and TCF-4 (Cell Signaling Technology, Inc.
Beverly, MA, United States). αtubulin and βactin (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, United States) were used as loading controls. The following horseradish peroxidaseconjugated antibodies were purchased from Santa Cruz Biotechnology, Inc. (CA, United States): goat anti-mouse IgG, goat antirabbit IgG, and rabbit anti-goat IgG. Nude mice were purchased from the National Laboratory Animal Center (NLAC).
Cell culture
The colon cancer cell line LoVo was cultured in 10cm 2 culture dishes in Dulbecco's modified Eagle's medium (DMEM) supplemented with 100 µg/mL penicillin, 100 µg/mL streptomycin, 2 mmol/L glutamine, 1 mmol/L HEPES buffer, and 10% fetal bovine serum (FBS) in humidified air (5% CO2) at 37 ℃.
Cell proliferation assay
LoVo cells were seeded at a density of 1. Louis MO, United States) dissolved in DMSO. An MTT (3(4,5Dimethylthiazol2yl)2,5diphenyltetrazolium bromide) assay was used to determine living cells 24 h after treatment. Culture supernatants were removed, and MTT (Sigma, United States) in phosphatebuffered saline (PBS, pH 7.4) was added to each well. After 4 h of incubation at 37 ℃, the MTT solution was removed, and DMSO was added to dissolve the resultant formazan crystals. Absorbance was read at 540 nm in a Flexstation 3 device (MDS Analytical Technologies, Canada). The percentage viability was calculated as (testbackground)/(controlbackground) × 100.
Immunoblotting assay
Cultured LoVo cells were washed with cold PBS and resuspended in lysis buffer [50 mmol/L Tris (pH 7.5), 0.5 mol/L NaCl, 1.0 mmol/L EDTA (pH 7.5), 10% glycerol, 1 mmol/L BME, 1% IGEPAL-630, and a proteinase inhibitor cocktail (Roche Molecular Biochemical)] to isolate total proteins. After incubation for 30 min on ice, the supernatant was collected by centrifugation at 12000 × g for 15 min at 4 ℃. Protein concentration was then determined using the Bradford method. Samples containing equal protein amounts (60 µg) were loaded and analyzed using immunoblotting analysis. Proteins were separated using 10% SDS PAGE and transferred onto PVDF membranes (Millipore, Belford, MA, United States). The membranes were blocked with blocking buffer (5% nonfat dry milk, 20 mmol/L TrisHCl, pH 7.6, 150 mmol/L NaCl, and 0.1% Tween 20) for at least 1 h at room temperature. The membranes were incubated with primary antibodies in the above solution on an orbital shaker at 4 ℃ overnight. Following the primary antibody incubations, the membranes were incubated with horseradish lower compartment was filled with DMEM containing 10% FBS. LoVo cells were placed in the upper part of the Boyden chamber, which contained serumfree medium, and incubated for 48 h. After incubation, cells on the membrane filter were fixed with methanol and stained with 0.05% Giemsa for 1 h. The cells on the upper filter surface were removed with a cotton swab. The filters were then rinsed in doubledistilled water for additional stain leaching. The cells were then airdried for 20 min. Migratory phenotypes were determined by counting the cells that migrated to the lower side of the filter using microscopy at 200 × and 400 × magnification. Ten fields were blindly selected and counted as the mean cell number in each filter. The sample was assayed in triplicate.
Study animals
Twelve nude mice were bred in the animal care facility of the Chinese Medicine Library (Taichung, Taiwan) and were purchased from The National Laboratory Animal Center. The animals received subcutaneous injections of LoVo colorectal cancer cells (1 × 10 6 cells per injection) in the back. Ambient temperature was maintained at 25 ℃, and the mice were kept on an artificial 12h lightdark cycle, with the light period beginning at 7:00 am. All of the protocols were approved by the Institutional Animal Care and Use Committee of China Medical University, Taichung, Taiwan, ROC.
LoVo cells were treated with PGE2 (5 µmol/L) for 24 h and were then injected subcutaneously into the mice (1 × 10 6 cells). After one week, various concentrations (0.5, 10 and 20 µmol/L) of TQ were administered for three weeks (3 times per week) by intraperitoneal injection. All protocols were reviewed and approved by the Institutional Review Board (IRB, ethical clearance number 104223N), Animal Care and Use Committee of China Medical University, Taichung, Republic of China, and the study was conducted in accordance with the principles of laboratory animal care [36] .
Statistical analysis
Each experiment was duplicated at least three times. The results are presented as the mean ± SE, and statistical comparisons were made using Student's t-test. Significance was defined at p < 0.05 or 0.01.
RESULTS
Effect of TQ on viability of LoVo cells
We first tested the effect of TQ on the viability of LoVo cells. Several TQ concentrations were used to evaluate cell viability after coculture for 24 h. The results indicated that 20 µmol/L TQ can significantly reduce LoVo cell proliferation (Figure 1 ).
p-PI3K-, p-Akt-, p-GSK3β -and β -catenin-induced COX-2 expression is down-regulated by TQ
Previous reports have demonstrated that PGE2 peroxidaselinked secondary antibodies (anti rabbit, anti-mouse, or anti-goat IgG). Detection was performed using ECL reagents and a digital imaging system.
Nuclear extraction
Cytoplasmic and nuclear fractions were obtained using extraction reagents containing membrane lysis buffer . Following treatment, the cells were resuspended in PBS, incubated with icecold membrane lysis buffer for 10 min, and centrifuged at 12000 rpm for 2 min to pellet nuclei. The supernatant was stored for use as a cytoplasmic fraction, and the nuclear pellet was lysed with nuclear lysis buffer to obtain a nuclear fraction.
Immunofluorescence assay
LoVo cells were treated with increasing TQ dosages (5, 10, and 20 µmol/L) for 24 h, and PGE2 (5 µmol/L) was added for the last six hours. An immunofluorescence assay was performed on the LoVo cells using a βcatenin antibody (1:250) directed against a target of interest. A fluorophore-conjugated secondary antibody (green) that was directed against the primary antibody was used for detection, and a blue fluorescent DAPI nuclear acid counterstain that preferentially stains dsDNA was included. Antiβcatenin (green) merged with DAPI (blue) is also shown in the resultant confocal microscopy images.
Migration assay
A migration assay was performed using a 48well Boyden chamber (Neuro Probe) plate with 8µm pore size polycarbonate membrane filters [35] . The increases COX2 expression via activation of the EP4/ β-catenin pathway, suggesting that PGE2 regulates p-PI3K, p-AKT, and p-GSK-3β expression in LoVo cells. PGE2 has been reported to activate downstream signaling via EP2 and EP4 to elicit various biological responses. As shown in Figure 2 , TQ treatment reduced the upregulation of COX2 expression by PGE2, and β-catenin had an obvious effect on EP2 and EP4 regulation by PGE2.
Effect of TQ on β -catenin translocation
βcatenin is a key protein that affects nuclear COX2 transcription. We used an immunofluorescence assay to evaluate βcatenin protein levels in the cytosol and nucleus. Confocal microscopy confirmed that TQ treatment led to the translocation of βcatenin into the LoVo cell nucleus (Figure 3 ).
Nuclear translocation inhibition of β -catenin in the LoVo cancer cell line
Previous studies have demonstrated that the trans location of βcatenin involves cointeraction with and activation of the promoters LEF-1 and TCF-4, which subsequently modulate downstream gene expression.
Evaluation of isolated LoVo cell nuclei showed that βcatenin translocation decreased in the nucleus, but its interactions with the cofactors LEF-1 and TCF-4 did not change. We observed a concentrationdependent decrease in the levels of βcatenin and the proteins LEF-1 and TCF-4 in the nucleus following TQ treatment ( Figure 4 ).
TQ treatment inhibits LoVo cell migration
Migration is an important step in LoVo colon cancer progression because this cancer metastasizes supra clavicular lymph nodes. We performed a Boyden chamber migration assay to determine the effect of TQ on LoVo cells and found that TQ inhibited LoVo cell migration in a dose-dependent manner ( Figure 5 ).
Effect of TQ on tumor growth in nude mouse xenografts
To verify previous results on the growth inhibition and antimetastatic effects of TQ in human LoVo cells, the therapeutic potential of TQ in a presubcutaneous LoVo cell model in nude mice was determined. TQ was administered for 30 consecutive days. The drug did not induce death or weight loss of more than 15% to 20% of original weight, which is a very sensitive parameter for perniciousness in mice. The effects of TQ on PGE2-associated protein markers for inflammation and metastasis in the nude mouse xenograft model were then determined. COX2 and βcatenin protein levels in different tissue groups in the nude mice were downregulated by TQ treatment in a concentration dependent manner ( Figure 6 ).
DISCUSSION
TQ was shown to be an anticancer agent by virtue of its antiproliferative potential and capacity to induce cell cycle arrest [37] . In our previous studies, COX2 protein was found to be regulated by PGE2, resulting in cell proliferation and migration. Here, a 20 µmol/L concentration of TQ, which is 50% of the noncytotoxic concentration determined by MTT assay, arrested the migration of LoVo colorectal cancer cells. We tested TQ on LoVo colorectal cancer cells that were already induced by PGE2 (5 µmol/L); these cells exhibited significantly enhanced performance over the control group. Our experimental drug TQ inhibited the survival pathway proteins p-PI3K, p-Akt, p-GSK3β, βcatenin and COX2.
When βcatenin is translocated from the cytosol into the nucleus, it plays a role in the transcription and translation of COX2 [28] . The translocation of βcatenin from the cytosol into the nucleus also plays a role in the transcription and translation of COX2.
Nuclear isolation techniques and immunofluo rescence were used to determine the localization of βcatenin and the COX2 transcription cofactors LEF-1 and TCF-4 [38] . Our experiments showed that TQ suppresses β-catenin translocation induced by PGE2, and the expression of both LEF-1 and TCF-4 was also suppressed. This result suggests that βcatenin loses its ability to translocate into the nucleus and bind to LEF-1 and TCF-4 following TQ treatment. These cofactors were also affected by TQ with a gradually declining, concentrationdependent trend. Immunofluorescence confocal microscopy showed We can observe the impact of TQ on COX2 by assessing these translation and transcription associated proteins. COX2 plays a central role in cell migration. These results showed that decreasing COX2 levels will correspondingly reduce cell migration.
In this context, we demonstrated that TQ significantly reduces metastasis in vivo. However, we investi gated the therapeutic potential of TQ using a highly aggressive human LOVO cancer cell xenograft nude mouse model. pAkt, βcatenin and COX2 expression substantially decreased. TQ inhibited LoVo colorectal cancer cell growth and inhibited migration. In the future, we will evaluate the therapeutic advantage of combining chemotherapeutic agents for colorectal cancer.
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Background
Several types of phytochemicals are used for cancer chemotherapy. The aim was to identify potential anti-cancer constituents in natural extracts that inhibit cancer cell growth and migration. Thymoquinone (TQ) is a phytochemical compound isolated from Nigella sativa. Previous data show that TQ suppresses the activation of AKT, inhibits cellular proliferation, and shows anti-oxidant/antiinflammatory effects.
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Prostaglandin E2 (PGE2) induces migration of human LoVo colon cancer cells, and the major mechanism involves the activation of the p-Akt/p-PI3K/p-GSK3β/ β-catenin/LEF-1/TCF-4 pathway that ultimately up-regulates cyclooxygenase 2 
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